Who will win Covid-19 vaccine race?

What happened?

Goldman Sachs claimed that vaccine developments tend to have more impact on the overall sentiment than even election results or Q3 earnings. We have had already a chance to observe how recent negative news weighed on the market sentiment. Johnson & Johnson announced that it has temporarily stopped the Covid-19 vaccine trials because of the unexplained illness of one participant. As a result, the market sentiment deteriorated, and the safe-haven US dollar rose today. However, the nature of the illness hasn’t been yet defined: a special committee is trying to find it out.

Actually, it has been the second-largest setback in the vaccine race so far. AstraZeneca halted human trials for a similar reason: a patient had an adverse reaction. Trials have been resumed in the UK, Brazil, India, and South Africa, while it remains on hold in the US as the Food and Drug Administration has been still investigating that case.

High-potential companies

Both AstraZeneca and Johnson & Johnson have created adenovirus-based vaccines. So, perhaps, biotech companies, which use other technologies will have a boost. For instance, Moderna is working on a vaccine, based on the technique of using messenger ribonucleic acid (mRNA). It is said that this technique has more advantages than traditional drug development by medical and manufacturing reasons.

By the way, BioNTech uses the same mRNA technique. Pfizer and BioNTech are creating the vaccine in collaboration, and two companies have announced that their vaccine has been accepted for a rolling review by Health Canada. It looks like Pfizer and BioNTech have all chances to win this rally. Don’t you think?

Forecasts from Goldman Sachs

Goldman Sachs gives the 71% of probability that the vaccine will be available for widespread distribution by the first quarter of 2021. Notably, the bank upgraded its forecasts from 39%, which it gave in August. Elsewhere, Goldman wrote in a note to its clients that it expects strong growth in such sectors as healthcare, consumer staples, and information tech companies. At the same time, the energy and industrials sectors are predicted to slump.

Technical tips

Pfizer is edging higher. It approaches the intersection of the 200-week moving average and the strong resistance level of $37.25, which it has failed to break in previous years. That’ why we can expect some sell-off around this area. Once the breakout happens, it will encourage buyers, and the price may surge to the recent high of $39.00. On the flip side, there is a 7-months support line which constrains the price to fall beyond. The move below September’s dips of $36.00 will push the price lower to the next support of $34.00.

Just look at great BioNTech’s performance. In comparison with other biotech giants as Pfizer, it’s a young company, but it has managed to rise enormously so far. BioNTech made its US stock market initial public offering last October 15, and it increased its value so much that it has been included in Nasdaq. The move above March’s high of $95.00 will drive the price to the record high of $105.00. Support levels are $76.00 and 70.00.

What should you do for trading BioNTech and Pfizer?

Trading stocks with FBS is easy. Follow the simple steps described below.

TRADE NOW

Author: FBS Analyst Team

Lainnya dari penulis ini

Menyerupai

18.02.2022 14:35 Minyak bisa mencapai $100, apa artinya bagi pasar dan inflasi?

Semakin banyak analis percaya bahwa minyak Brent akan melampaui $100 per barel. Jadi, seberapa kuat minyak akan menggerakkan pasar, dan bagaimana arah pergerakannya? Mari kita cari tahu!

31.08.2021 03:40 Faktor Kesehatan dan Politik Membuat USDJPY Cenderung Menguat

Pemerintah Jepang sebelum nya 1,63 juta dosis vaksin moderna di tangguhkan penggunaannya karena ada partikel dalam cairan vaksin Maka kembali 1 juta vaksin dengan merk yang sama harus ditarik karena terdapat partikel hitam dan merah muda…

09.08.2021 03:56 AUDUSD Melemah Ditengah Penguatan US Dollar

Pada hari jumat data sector tenaga kerja Amerika Serikat terlihat sangat kuat, Data lowongan pekerjaan diluar sector pertanian menjadi 943K dari hasil revisi 938K pada bulan Juni dan angka tingkat pengangguran turun dari 5,9% menjadi 5,4%…

Berita terbaru

02.04.2024 07:03 Yen Terus Terpuruk Mendekati Level Terendah Multi-Dekade

Yen Jepang gagal memikat para investor pada perdagangan Selasa (02/04/2024) meski ada peluang atas kemungkinan intervensi dan..Sentimen penghindaran risiko masih berpotensi memberikan kekuatan pada safe-haven

01.04.2024 08:22 Sanggupkan Emas Berlama-lama di Puncak?

XAUUSD naik ke rekor tertinggi baru pada perdagangan Senin (01/04/2024), di tengah meningkatnya spekulasi penurunan suku bunga..melanjutkan kenaikan kuat minggu lalu hingga membentuk level puncak baru sepanjang masa

01.04.2024 07:11 Sebagian Pasar Masih Libur, Yen Stabil di Bawah 152

Pasar saham Asia sebagian masih libur dan sebagian lagi menguat pada perdagangan Senin (01/04/2024), karena optimisme data pabrikan Tiongkok mendukung..potensi intervensi otoritas Jepang terhadap yen Jepang diperkirakan berada di zona 152 – 155 yen.